Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.42 |
| ▸ | MPO | P05164 | 2/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403060 | 0.94 | HTR1A (0.43) | HTR1ASLC6A4HCRTR1HCRTR2MPO | |
| SCHEMBL2403179 | 0.94 | HTR1A (0.43) | HTR1ASLC6A4HCRTR1HCRTR2MPO | |
| SCHEMBL2405504 | 0.93 | HTR1A (0.43) | HTR1ASLC6A4HCRTR1HCRTR2MPO | |
| SCHEMBL2403381 | 0.92 | HTR1A (0.46) | HTR1ASLC6A4HCRTR1HCRTR2MPO | |
| SCHEMBL2406057 | 0.91 | HTR1A (0.45) | HTR1ASLC6A4HCRTR1HCRTR2MPO | |
| SCHEMBL2409978 | 0.90 | HTR1A (0.44) | HTR1ASLC6A4HCRTR1HCRTR2MPO | |
| SCHEMBL2407412 | 0.90 | HTR1A (0.42) | HTR1ASLC6A4HCRTR1HCRTR2MPO | |
| SCHEMBL2403617 | 0.90 | HTR1A (0.47) | HTR1ASLC6A4MPO | |
| SCHEMBL2407858 | 0.89 | HTR1A (0.44) | HTR1ASLC6A4HCRTR2MPO | |
| SCHEMBL2406133 | 0.89 | HTR1A (0.43) | HTR1ASLC6A4HCRTR1HCRTR2MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HTR1A 56/4885SLC6A4 781/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.